About collplant biotechnologies - CLGN
CollPlant Biotechnologies Ltd. operates as a regenerative and aesthetic medicine company. It engages in the research, development, manufacture, and marketing of medical products for tissue repair such as bioprinting of tissues and organs, and medical aesthetics. Its products include VergenixSTR, VergenixFG, and Collink.3D. The company was founded by Oded Shoseyov in June 2004 and is headquartered in Rehovot, Israel.
CLGN At a Glance
CollPlant Biotechnologies Ltd.
Weizmann Science Park
Rehovot, Tel Aviv 7670104
| Phone | 972-73-232-5600 | Revenue | 2.37M | |
| Industry | Medical Specialties | Net Income | -11,489,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 360.388% | |
| Fiscal Year-end | 12 / 2026 | Employees | 39 | |
| View SEC Filings |
CLGN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 7.206 |
| Price to Book Ratio | 2.948 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.323 |
| Enterprise Value to Sales | 5.896 |
| Total Debt to Enterprise Value | 0.204 |
CLGN Efficiency
| Revenue/Employee | 60,794.872 |
| Income Per Employee | -294,589.744 |
| Receivables Turnover | 2,371.00 |
| Total Asset Turnover | 0.161 |
CLGN Liquidity
| Current Ratio | 2.525 |
| Quick Ratio | 2.311 |
| Cash Ratio | 2.227 |
CLGN Profitability
| Gross Margin | 26.318 |
| Operating Margin | -484.31 |
| Pretax Margin | -484.563 |
| Net Margin | -484.563 |
| Return on Assets | -77.905 |
| Return on Equity | -117.559 |
| Return on Total Capital | -128.699 |
| Return on Invested Capital | -96.332 |
CLGN Capital Structure
| Total Debt to Total Equity | 46.802 |
| Total Debt to Total Capital | 31.881 |
| Total Debt to Total Assets | 26.389 |
| Long-Term Debt to Equity | 33.416 |
| Long-Term Debt to Total Capital | 22.762 |